3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
NIH
2
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
242
Neoplasms, Plasma Cell
50
Lymphoma
45
Lymphoma, Mantle-Cell
40
Precursor Cell Lymphoblastic Leukemia-Lymphoma
31
Lymphoma, Non-Hodgkin
30
Recurrence
29
Lymphoma, Follicular
24
Leukemia, Myeloid, Acute
24
Lymphoma, Large B-Cell, Diffuse
23
Waldenstrom Macroglobulinemia
22
Lymphoma, B-Cell, Marginal Zone
20
Leukemia
20
Immunoglobulin Light-chain Amyloidosis
18
Leukemia, Lymphocytic, Chronic, B-Cell
14
Myelodysplastic Syndromes
12
Carcinoma, Non-Small-Cell Lung
12
Neoplasms
11
Hodgkin Disease
11
Burkitt Lymphoma
10
Breast Neoplasms
10
Lymphoma, T-Cell, Peripheral
9
Lymphoma, Large-Cell, Anaplastic
9
Lymphoma, B-Cell
9
Lung Neoplasms
9
Immunoblastic Lymphadenopathy
9
Hematologic Neoplasms
9
Prostatic Neoplasms
8
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
8
Lymphoma, T-Cell
8
Interventions
pembrolizumab
2
fludarabine
2
Radiosurgery
2
Paclitaxel
2
Gemcitabine
2
Cyclophosphamide
2
Cisplatin
2
Carboplatin
2
Anthropogenic Effects
2
venetoclax
1
umbralisib
1
ublituximab
1
regorafenib
1
pazopanib
1
niraparib
1
neratinib
1
lutetium Lu 177 dotatate
1
ibrutinib
1
grapiprant
1
fludarabine phosphate
1
famitinib
1
encorafenib
1
copanlisib
1
cemiplimab
1
capivasertib
1
camrelizumab
1
brigatinib
1
binimetinib
1
axicabtagene ciloleucel
1
avelumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Disease Progression
×
Bortezomib
×
Clear all
NCT01191060
2026-04-06
IFM/DFCI2009
University Hospital, Toulouse
Phase 3
Completed
700 enrolled